Invert Sugar
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Invert Sugar: From an Unspecified Original Indication to Sclerosing Cholangitis
One-Sentence Summary
Invert sugar is an equimolar mixture of glucose and fructose, generally used as a carbohydrate and fluid source, and no approved indication is recorded in the data compiled for this report. The TxGNN model predicts it may be effective for sclerosing cholangitis, but no clinical trials and no publications currently support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the approved indication text of both registrations is blank) |
| Predicted New Indication | Sclerosing cholangitis |
| TxGNN Prediction Score | 0.9962 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Invert sugar is an equimolar mixture of glucose and fructose, used mainly as a carbohydrate and fluid source, including in parenteral nutrition. It has no known anti-cholestatic, anti-inflammatory, or immunomodulatory activity relevant to sclerosing cholangitis.
No mechanistic link to sclerosing cholangitis can be established from the available data. The very high TxGNN score (0.9962) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
There is also a plausible safety concern. Fructose and high-dose parenteral dextrose are associated with hepatic steatosis and parenteral nutrition-associated liver disease. This should be weighed carefully before any further consideration in a liver and biliary disease.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 187792 | Rgnil Syrup | Bottle of 100 ml syrup | Not stated |
| 192761 | Rgnil Syrup | Bottle of 60 ml syrup | Not stated |
Both registrations are valid single-ingredient products from Unicure Remedies Pvt Ltd.
Safety Considerations
Please refer to the package insert for safety information.
Hepatic safety is a theoretical concern. Fructose and high-dose parenteral dextrose have been linked to hepatic steatosis and parenteral nutrition-associated liver disease. This is a general pharmacological consideration, not a finding from the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5). There are no clinical trials, no literature, and no plausible mechanistic link, and a potential hepatic safety concern exists. The drug’s original indication is also not documented.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India regulator’s records, which are needed for safety screening
- Mechanism of action data for invert sugar
- The approved indications for the two registered products
- A literature and trial search for any link between invert sugar, fructose, or glucose and sclerosing cholangitis
- A hepatic safety assessment, given the known liver effects of fructose and parenteral dextrose
- Confirmation of route compatibility, which has not yet been assessed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.